Texas upstart XBiotech made a string of embarrassing mistakes in a Phase III trial on its lead cancer therapy, misdosing some patients and failing to adequately test others on the way to a staggering mishap.
Scientists coated nanospheres of paclitaxel with a peptide shell that stays intact as it travels through the circulatory system and is then split open by enzymes known to spur metastasis. The drug can then be directed straight to cancer cells at 16 times the regular dose, halting tumor growth.
Japanese drugmaker Takeda is angling to win FDA approval for its lead cancer asset, an oral treatment for blood malignancies that is key to the company's future in oncology.
Agios Pharmaceuticals' lead cancer drug extended its streak of promising clinical results, racking up remissions in an expanded Phase I trial as the company prepares for late-stage testing.
Investigators at the Winship Cancer Institute at Emory University say they've found a new molecule that appeared to do better than an inhibitor in preclinical in vivo testing.
Bayer is plotting a pair of Phase III trials for its lead oncology treatment, hoping to crack the crowded field of new blood cancer drugs with a targeted therapy of its own.
Upstart cancer drug developer Aura Biosciences has rounded up $21 million for its Series B, attracting a large group of backers and keeping former Genzyme CEO and ubiquitous biotech investor Henri Termeer in the game.
Multidrug resistance to the chemotherapies in wide use today is a lethal problem. As patients stop responding to drugs, they become increasingly vulnerable to a deadly assault. Now investigators at The Scripps Research Institute say they have illuminated a key protein that plays a big role in promoting drug resistance, offering a new approach for investigators designing the next generation of new and improved cancer therapies that won't eventually be disarmed.
North Carolina's G1 Therapeutics hauled in $33 million to advance a headline-grabbing approach to cancer treatment, helping the biotech hit the gas in a space otherwise dominated by Big Pharma.
A group of scientists at Dana-Farber Cancer Institute say they may have a lead on a pair of biomarkers that could help predict the likelihood of extending progression-free survival in multiple myeloma patients. And their work may help guide the development of future treatments.